NAV

LJP 1082

Identification

Generic Name
LJP 1082
DrugBank Accession Number
DB05446
Background

LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. LJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. Antibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood clotting disorder. Patients with high levels of anticardiolipin antibodies (ACA) have an increased risk of stroke, heart attack, deep vein thrombosis, and recurrent fetal loss. The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. To date, our scientists have shown that approximately 90% of patients studied with antibody-mediated thrombosis have antibodies that bind to this region.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 337.349
Monoisotopic: 337.094370667
Chemical Formula
C11H19N3O7S
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

LJP 1082, a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

Mechanism of action

The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.

TargetActionsOrganism
UBeta-2-glycoprotein 1Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Gamma-glutamyl peptides / Glutamine and derivatives / N-acyl-alpha amino acids / Alpha amino acid amides / Cysteine and derivatives / Alpha amino acids / N-acyl amines / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Secondary carboxylic acid amides
show 8 more
Substituents
Aliphatic acyclic compound / Alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Alpha-oligopeptide / Amine / Amino acid / Amino acid or derivatives / Carbonyl group / Carboxamide group
show 24 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
PIUSLWSYOYFRFR-UHFFFAOYSA-N
InChI
InChI=1S/C11H19N3O7S/c12-6(11(20)21)1-2-8(16)14-7(4-22-5-15)10(19)13-3-9(17)18/h6-7,15H,1-5,12H2,(H,13,19)(H,14,16)(H,17,18)(H,20,21)
IUPAC Name
2-amino-4-({1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl}carbamoyl)butanoic acid
SMILES
NC(CCC(=O)NC(CSCO)C(=O)NCC(O)=O)C(O)=O

References

General References
  1. Cockerill KA, Iverson GM, Jones DS, Linnik MD: Therapeutic potential of toleragens in the management of antiphospholipid syndrome. BioDrugs. 2004;18(5):297-305. [Article]
  2. Merrill JT: LJP 1082: a toleragen for Hughes syndrome. Lupus. 2004;13(5):335-8. [Article]
  3. Bayes M, Rabasseda X, Prous JR: Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. [Article]
PubChem Compound
1082
PubChem Substance
175427006
ChemSpider
1052

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.27 mg/mLALOGPS
logP-3.2ALOGPS
logP-5.5Chemaxon
logS-1.8ALOGPS
pKa (Strongest Acidic)1.79Chemaxon
pKa (Strongest Basic)9.31Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area179.05 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity75.2 m3·mol-1Chemaxon
Polarizability32.24 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.6042
Blood Brain Barrier+0.7027
Caco-2 permeable-0.7886
P-glycoprotein substrateNon-substrate0.5273
P-glycoprotein inhibitor INon-inhibitor0.8919
P-glycoprotein inhibitor IINon-inhibitor0.9927
Renal organic cation transporterNon-inhibitor0.935
CYP450 2C9 substrateNon-substrate0.9126
CYP450 2D6 substrateNon-substrate0.8176
CYP450 3A4 substrateNon-substrate0.75
CYP450 1A2 substrateNon-inhibitor0.9278
CYP450 2C9 inhibitorNon-inhibitor0.9088
CYP450 2D6 inhibitorNon-inhibitor0.9362
CYP450 2C19 inhibitorNon-inhibitor0.8956
CYP450 3A4 inhibitorNon-inhibitor0.8613
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9939
Ames testAMES toxic0.5732
CarcinogenicityNon-carcinogens0.9104
BiodegradationReady biodegradable0.7095
Rat acute toxicity1.9135 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9833
hERG inhibition (predictor II)Non-inhibitor0.9446
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-01po-6291000000-700a78b68cd3c72dace0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0189000000-a1a4eca9b7d5f4bd9d0c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0ab9-1592000000-45254ba2ca53b37a177e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03ec-9850000000-0fcce70f1ff0d2a0601f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0zgu-2971000000-22e081b68163df0081b6
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03dl-9500000000-12fc1e6e81c1df48b2d5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-9210000000-a9e5f3107614e2995e3a
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-172.19498
predicted
DeepCCS 1.0 (2019)
[M+H]+174.55296
predicted
DeepCCS 1.0 (2019)
[M+Na]+180.64612
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Beta-2-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Phospholipid binding
Specific Function
Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phosphol...
Gene Name
APOH
Uniprot ID
P02749
Uniprot Name
Beta-2-glycoprotein 1
Molecular Weight
38297.8 Da

Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52